| Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized … S Rögnvaldsson, TJ Love, S Thorsteinsdottir, ER Reed, JÞ Óskarsson, ... Blood Cancer Journal 11 (5), 94, 2021 | 72 | 2021 |
| Prevalence of smoldering multiple myeloma based on nationwide screening S Thorsteinsdóttir, GK Gíslason, T Aspelund, S Rögnvaldsson, ... Nature medicine 29 (2), 467-472, 2023 | 31 | 2023 |
| Bromotryptamine and Imidazole Alkaloids with Anti-inflammatory Activity from the Bryozoan Flustra foliacea X Di, S Wang, JT Oskarsson, C Rouger, D Tasdemir, I Hardardottir, ... Journal of Natural Products 83 (10), 2854-2866, 2020 | 25 | 2020 |
| Screening for monoclonal gammopathy of undetermined significance: a population-based randomized clinical trial. First results from the Iceland Screens, Treats, or Prevents … SY Kristinsson, S Rögnvaldsson, S Thorsteinsdottir, ER Reed, ... Blood 138, 156, 2021 | 18 | 2021 |
| Lipophilic fractions from the marine sponge Halichondria sitiens decrease secretion of pro-inflammatory cytokines by dendritic cells and decrease their ability to induce a Th1 … X Di, JT Oskarsson, S Omarsdottir, J Freysdottir, I Hardardottir Pharmaceutical biology 55 (1), 2116-2122, 2017 | 13 | 2017 |
| Evaluation of multiple myeloma measurable residual disease by high sensitivity flow cytometry: an international harmonized approach for data analysis KT Soh, N Came, GE Otteson, D Jevremovic, M Shi, H Olteanu, A Natoni, ... Cytometry Part B: Clinical Cytometry 102 (2), 88-106, 2022 | 12 | 2022 |
| Correction: Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and … S Rögnvaldsson, TJ Love, S Thorsteinsdottir, ER Reed, JÞ Óskarsson, ... Blood Cancer Journal 13 (1), 2023 | 9 | 2023 |
| Prevalence of smoldering multiple myeloma: results from the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) study S Thorsteinsdottir, GK Gislason, T Aspelund, S Rögnvaldsson, ... Blood 138 (Supplement 1), 151-151, 2021 | 9 | 2021 |
| Monitoring of circulating tumor plasma cells in patients with precursor conditions of multiple myeloma: Data from the Prospective Iceland Screens, Treats, or Prevents Multiple … JÞ Óskarsson, I Petursdottir, S Rögnvaldsson, S Thorsteinsdottir, ... Blood 138, 2645, 2021 | 2 | 2021 |
| Immunophenotypic assessment of clonal plasma cells and B-cells in bone marrow and blood in the diagnostic classification of early stage monoclonal gammopathies: an iSTOPMM study O Pérez-Escurza, J Flores-Montero, JÞ Óskarsson, L Sanoja-Flores, ... Blood Cancer Journal 13 (1), 182, 2023 | 1 | 2023 |
| Determining hemodilution in diagnostic bone marrow aspirated samples in plasma cell disorders by next-generation flow cytometry: Proposal for a bone marrow quality index JÞ Óskarsson, S Rögnvaldsson, S Thorsteinsdottir, T Aspelund, ... Blood cancer journal 13 (1), 177, 2023 | 1 | 2023 |
| The early benefits and psychological effects of screening for monoclonal gammopathy of undetermined significance: results of the istopmm study S Rögnvaldsson, S Thorsteinsdottir, J Oskarsson, E Eythorsson, ... Blood 142, 214, 2023 | 1 | 2023 |
| Determining Hemodilution in Diagnostic Bone Marrow Samples in Multiple Myeloma and Its Precursors by Next-Generation Flow Cytometry: Data from the Iceland Screens, Treats, or … JÞ Óskarsson, S Rögnvaldsson, S Thorsteinsdóttir, GK Hakonardottir, ... Blood 140 (Supplement 1), 7166-7167, 2022 | 1 | 2022 |
| Transient M-proteins: epidemiology, causes, and the impact of mass spectrometry: the Istopmm study R Palmason, O Berlanga, JK Sigurdsson, S Rögnvaldsson, ... Blood 140 (Supplement 1), 2338-2340, 2022 | 1 | 2022 |
| Author Correction: Prevalence of smoldering multiple myeloma based on nationwide screening (Nature Medicine,(2023), 29, 2,(467-472), 10.1038/s41591-022-02183-6) S Thorsteinsdóttir, GK Gíslason, T Aspelund, S Rögnvaldsson, ... | | 2023 |
| Author Correction: Prevalence of smoldering multiple myeloma based on nationwide screening S Thorsteinsdóttir, GK Gíslason, T Aspelund, S Rögnvaldsson, ... Nature medicine 29 (12), 3269, 2023 | | 2023 |
| Monoclonal Gammopathy of Undetermined Significance and the Risk of Thrombotic Events: Results from Istopmm, a Population-Based Screening Study in Iceland S Rögnvaldsson, A Gasparini, S Thorsteinsdottir, I Sverrisdottir, ... Blood 142 (Supplement 1), 216-216, 2023 | | 2023 |
| Risk Factors of Smoldering Multiple Myeloma: Results from the Screened Istopmm Study S Thorsteinsdottir, I Sverrisdottir, S Rögnvaldsson, S Ekberg, M Hultcrantz, ... Blood 142 (Supplement 1), 3397-3397, 2023 | | 2023 |
| Predicting an Underlying Clonal Plasma Cell Population in Light-Chain Monoclonal Gammopathy of Undetermined Significance Using Free Light-Chain Ratio JT Oskarsson, S Rögnvaldsson, S Thorsteinsdottir, TE Long, ... Blood 142, 530, 2023 | | 2023 |
| Sars-Cov-2 Infection Does Not Lead to Progression of Monoclonal Gammopathy of Undetermined Significance: Results from the Population-Based Istopmm Screening Study R Palmason, S Ekberg, E Eythorsson, S Rögnvaldsson, S Thorsteinsdottir, ... Blood 142, 4766, 2023 | | 2023 |
